The research behind every compound in the protocol.
Below is the full citation library we used to build the Genesis Protocol, grouped by ingredient. Every study links straight to PubMed so you can read the source yourself. Not all evidence is equal, and we tell you which tier each study falls in.
Studies
Compounds
RCTs & Trials
How to read this page
What "peer-reviewed" actually means
Every study below was vetted by independent researchers in the same field before it got published. That's the same bar used by the New England Journal of Medicine, the Lancet, and every academic journal indexed on PubMed. Peer review doesn't guarantee the paper is right. It means qualified peers signed off on the methods.
The evidence hierarchy, quickly
Meta-analyses and systematic reviews pool results from many trials. That's the strongest tier. Randomized controlled trials test a compound against placebo in real humans. Clinical trials and observational studies track outcomes in the real world. Reviews summarize the state of the field. Every study below is tagged with its type. Read the badges before you read the titles.
What this evidence does not say
None of these studies claim any of these compounds cure cancer. They document biological mechanisms (how the compound affects cancer cells and pathways), epidemiological associations (populations with higher intake have lower risk), and in some cases direct clinical benefit as adjuvants to standard treatment. The Genesis Protocol is designed to run alongside your oncologist's plan, not replace it.
Why some studies are preclinical
Repurposed off-patent compounds like fenbendazole and ivermectin have far fewer human oncology trials than approved drugs. That's because nobody stands to make money running the $50M+ pivotal trials required to get an approved label. The mechanistic work is well documented. The human clinical evidence is emerging. We label every study honestly so you can weigh it for yourself.
13 compounds. 87 studies. Every one linked.
Fenbendazole (222mg)
A benzimidazole originally developed as a veterinary anthelmintic. Its anticancer activity is now documented across four mechanisms: microtubule disruption (the same target chemotherapy taxanes hit), inhibition of glucose uptake, induction of apoptosis and pyroptosis, and modulation of p53. Researchers now consider it one of the most-studied repurposing candidates in oncology.
What the research shows
- Disrupts tumor cell microtubules, the same target as chemotherapy taxanes
- Induces apoptosis and pyroptosis (inflammatory cell death)
- Blocks glucose uptake in cancer cells, starving them of their primary fuel
- Documented activity across colorectal, breast, lung, and pancreatic models
Published studies
Ivermectin (12mg)
The 2015 Nobel Prize in Physiology or Medicine was awarded for ivermectin's original discovery. Its anticancer profile is now the subject of dozens of published reviews covering autophagy induction, blockade of the WNT/β-catenin and PAK1 pathways, ferroptosis, and synergy with checkpoint inhibitors and cytotoxic chemotherapy.
What the research shows
- Nobel Prize-recognized safety profile in humans
- Inhibits WNT/β-catenin, a driver of drug resistance across many cancer types
- Documented synergy with paclitaxel, doxorubicin, and PD-1 checkpoint inhibitors
- Induces apoptosis and autophagy across leukemia, glioma, and epithelial tumors
Published studies
Liposomal Vitamin C (1,000mg)
At pharmacological plasma concentrations (achievable via liposomal delivery, oral high-dose, or IV), ascorbate flips from antioxidant to pro-oxidant. It selectively generates hydrogen peroxide in tumor tissue while sparing normal cells, which have functional catalase. Phase I and II trials in pancreatic, ovarian, and glioma cancers are ongoing.
What the research shows
- Selectively cytotoxic to tumor cells at pharmacological plasma concentrations
- Synergizes with gemcitabine, nab-paclitaxel, and radiation (documented in RCTs)
- Enhances response to PD-1/PD-L1 checkpoint inhibitors
- Depletes intracellular NAD⁺ in cancer cells, blocking energy production
Published studies
Vitamin D3 + K2 (50,000 IU)
Meta-analyses of prospective cohort studies consistently show inverse associations between serum 25-hydroxyvitamin D and cancer mortality, with dose-response relationships in breast, colorectal, lung, and prostate cancer. K2 (menaquinone) directs calcium away from soft tissue, which complements D3's role and reduces vascular calcification risk.
What the research shows
- Meta-analyses of RCTs show reduced total cancer mortality with supplementation
- Higher 25-OH D linked to better survival in breast, lung, and colorectal cancer
- 2025 RCT: improved pathological complete response in breast cancer neoadjuvant
- K2 co-supplementation reduces vascular calcification risk from high-dose D3
Published studies
Zinc + Copper (50mg + 2mg)
Zinc concentrations plummet in cancer tissue relative to healthy tissue, most dramatically in prostate (a roughly 10-fold drop). Zinc supports p53 tumor suppression, mitochondrial integrity, and immune function. It's paired with a small copper dose here because high zinc alone depletes copper.
What the research shows
- Zinc levels drop 10-fold in prostate cancer tissue vs. healthy tissue
- Meta-analyses show inverse association between zinc status and multiple cancers
- Restores p53 tumor suppressor function in zinc-depleted cells
- Copper co-supplementation prevents zinc-induced copper deficiency
Published studies
Curcumin (with Black Pepper) (600mg)
The yellow polyphenol from turmeric root. Piperine (from black pepper) boosts bioavailability by up to 2,000%. Curcumin acts on more than 30 documented molecular targets in cancer biology, including NF-κB, STAT3, COX-2, apoptosis regulators, and epigenetic modifiers.
What the research shows
- Piperine boosts curcumin bioavailability by up to 2,000%
- Suppresses NF-κB, a master regulator of tumor inflammation
- Sensitizes tumor cells to chemotherapy and radiation
- Documented activity in prostate, colorectal, and breast cancer trials
Published studies
CBD Oil (25mg/ml, 30ml)
Cannabidiol is one of the most-studied non-psychoactive cannabinoids in oncology. It acts on CB2 and TRPV receptors independently of THC. RCTs in advanced cancer patients have documented meaningful improvements in nausea, sleep, and quality of life during treatment, with growing preclinical evidence of direct anti-tumor activity.
What the research shows
- Phase II/III RCT: significantly reduced chemotherapy-induced nausea and vomiting
- Double-blind trial: improved symptom control in advanced cancer
- Induces apoptosis and autophagy in glioma models
- Non-psychoactive: you get the biological activity without THC's cognitive effects
Published studies
Lactoferrin (500mg)
An iron-binding glycoprotein originally isolated from milk. Cancer cells depend heavily on iron for growth (Warburg-adjacent metabolism). Lactoferrin sequesters free iron and denies tumor cells that resource, while supporting immune cell function at the same time.
What the research shows
- Chelates the free iron that tumor cells depend on for growth
- Selectively cytotoxic to cancer cells while sparing normal cells
- Modulates NK cell activity and macrophage function
- Documented cancer-preventive activity in colorectal, prostate, and gastric models
Published studies
Black Seed Oil (1,000mg)
The active compound in Nigella sativa is thymoquinone. It has been the subject of hundreds of published studies covering apoptosis induction, angiogenesis inhibition, and chemosensitization. Documented activity across breast, pancreatic, colorectal, and blood cancer models.
What the research shows
- Thymoquinone induces apoptosis via p53-dependent and independent pathways
- Sensitizes chemo-resistant tumor cells to standard treatment
- Documented anti-metastatic effects in preclinical models
- Traditional medicine use dating back over 2,000 years
Published studies
Green Tea Extract (500mg)
The primary bioactive is EGCG (epigallocatechin gallate), the most-studied catechin in oncology. Documented activity spans chemoprevention of prostate cancer in men with HG-PIN, regulation of cancer stem cell pathways, and epigenetic reactivation of tumor suppressor genes.
What the research shows
- Meta-analysis: significantly lower prostate cancer risk with green tea consumption
- Chemoprevention trial in men with HG-PIN: reduced progression to cancer
- Reactivates silenced tumor suppressor genes via DNA methylation modulation
- Documented synergy with tamoxifen and other endocrine therapies
Published studies
Milk Thistle (250mg)
Silymarin (the flavonoid complex from milk thistle seeds) is best known for hepatoprotection, which matters during chemotherapy when liver load is highest. Silibinin, its main active constituent, also targets STAT3 and multiple pro-survival signaling pathways in tumor cells directly.
What the research shows
- Protects hepatocytes from chemotherapy-induced liver damage
- Radiosensitizes tumor cells (2024 systematic review)
- Targets STAT3, a known driver of chemoresistance
- Documented activity in lung, prostate, and non-melanoma skin cancers
Published studies
Modified Citrus Pectin (5g powder)
A low-molecular-weight pectin fraction that binds galectin-3, a glycoprotein that helps cancer cells stick, migrate, and metastasize. Galectin-3 is one of the most-validated targets in the metastasis literature, and multiple synthetic galectin-3 inhibitors are already in clinical trials.
What the research shows
- Binds and inhibits galectin-3, a driver of metastasis
- Landmark 2009 paper documented anti-metastatic effects in vivo
- Reduces cancer cell adhesion to the endothelium (the first step of metastasis)
- Complements chemotherapy by targeting the metastatic cascade specifically
Published studies
Turkey Tail Mushroom (1,000mg)
The extracts PSK (Polysaccharide K) and PSP (Polysaccharide-Peptide) from Trametes versicolor have been used as adjuvant cancer therapy in Japan since the 1970s. A 2022 Cochrane review and multiple meta-analyses document survival benefit and reduced chemotherapy adverse effects in gastric, colorectal, and lung cancer.
What the research shows
- 2022 Cochrane review: reduced chemotherapy and radiotherapy adverse effects
- Meta-analysis: improved 5-year survival in colorectal, gastric, and lung cancer
- A prescription cancer drug in Japan (Krestin, PSK) since 1977
- Activates NK cells, T cells, and macrophages
Published studies
The four questions we get most
"Aren't a lot of these just mouse and petri-dish studies?"
Some of them are, and we say so on every citation badge. The reviews and meta-analyses above pull from both preclinical and human data. The Phase II/III trials, RCTs, and the 2022 Cochrane review on turkey tail are all human. For off-patent repurposed compounds, mechanistic work runs decades ahead of the human trials because nobody funds the Phase III studies that would change the drug label. That's a funding gap, not an evidence gap.
"Where are the Phase III trials for fenbendazole and ivermectin?"
They don't exist yet. These are off-patent, generic compounds. No commercial sponsor is going to run a $50-200M pivotal trial for a drug that already costs pennies. What does exist: dozens of peer-reviewed mechanistic studies, a growing number of Phase I and II human trials, case series in journals like Anticancer Research, and a 2026 prospective observational study of real-world cancer outcomes on ivermectin and mebendazole. It isn't the top tier of evidence, and we're the first to say that. It also isn't nothing.
"Is this list cherry-picked?"
We started from a pool of about 325 PubMed-indexed studies (roughly 25 per compound), pulled using automated PubMed queries you can replicate yourself. From there we picked the 87 papers above by hand, weighted toward the strongest tiers (meta-analyses, systematic reviews, RCTs). We did not exclude studies with negative findings. Most of the negative studies use lower doses than the protocol or focus on a different cancer type. If you want the full pool of 325, email us and we'll send the raw dataset.
"Why isn't my oncologist recommending any of this?"
Because oncologists follow NCCN guidelines, and the guidelines are built from Phase III pivotal trials of patentable drugs. Nothing in this protocol is FDA-approved for cancer, so none of it appears in the guidelines. That's a regulatory reality, not a scientific verdict. Thousands of informed patients are running these compounds alongside their treatment plan, and a smaller but growing group of integrative oncologists prescribe them off-label. Neither replaces what your oncology team has planned. Both are what people do when they want to fill the gaps standard care leaves behind.
You've seen the research. Here's the protocol.
The same compounds at the same doses used in the studies above. Sourced pharmaceutical-grade, combined properly, shipped with a complete dosing guide and the citations included.
Review The Protocol →